Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Zymeworks Inc
(NY:
ZYME
)
6.430
UNCHANGED
Last Price
Updated: 7:00 PM EST, Dec 15, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Zymeworks Inc
< Previous
1
2
3
4
Next >
Zymeworks to Host Third Quarter Results Conference Call
October 18, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Completes Plan to Become Delaware Corporation
October 13, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Results of Special Meeting
October 07, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Reminds Shareholders to Vote FOR its Redomicile
October 04, 2022
From
Zymeworks
Via
Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences and Early Research & Development Day
October 03, 2022
From
Zymeworks Inc.
Via
Business Wire
Independent Proxy Advisory Firm ISS Recommends a Vote FOR the Zymeworks Redomicile
September 26, 2022
From
Zymeworks Inc.
Via
Business Wire
Independent Proxy Advisory Firm Glass Lewis Recommends Zymeworks Shareholders Vote FOR Redomicile
September 16, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Reports Preliminary Phase 1 Trial Results for Zanidatamab Zovodotin (ZW49) at European Society for Medical Oncology Annual Congress
September 12, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
September 08, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Release of ESMO Abstract for Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers
September 04, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences
August 01, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
July 25, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
July 22, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks to Host Second Quarter Results Conference Call
July 21, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Plan to Become a Delaware Corporation
July 15, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
June 27, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
June 10, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Participation in Upcoming Investor Conference
May 27, 2022
From
Zymeworks Inc.
Via
Business Wire
Clinical Data Demonstrating Promising Antitumor Activity with Zanidatamab in 1L Setting of HER2‑Positive Breast and Gastroesophageal Cancers to be Presented at ASCO 2022
May 26, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks’ Board of Directors Unanimously Rejects Unsolicited, Non-Binding Proposal
May 20, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 04, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences
May 02, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Confirms Receipt of Unsolicited, Non-Binding Proposal from All Blue Falcons
April 28, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
April 28, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks to Host First Quarter 2022 Results Conference Call
April 19, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Announces Participation in Upcoming Investor Conferences
April 01, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
February 24, 2022
From
Zymeworks Inc.
Via
Business Wire
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
February 08, 2022
From
Zymeworks Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.